MTOR and hepatocellular carcinoma: First, PPa extract used in combination with sorafenib reduced AKT, pAKT (Ser473), mTOR, p-mTOR (Ser2448), P70S6K, and p-P70S6K (Ser411) expression, suggesting that the combination might inhibit HCC cell growth by suppressing the AKT/mTOR signaling pathway.